Joy Murphy
Primary Care · Saint Louis, MONPI 1851321103
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,276 and has fallen 80.5% since, to $444 in 2025. Among primary care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novo Nordisk$1K
- Amgen$1K
- Dexcom, Inc.$758
- AbbVie$620
- Nevro Corp.$288
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,833100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 50 | $1,190 |
| Novo Nordisk | 57 | $1,113 |
| Amgen | 59 | $1,103 |
| Dexcom, Inc. | 52 | $758 |
| AbbVie | 40 | $620 |
| Nevro Corp. | 11 | $288 |
| Lilly USA, LLC | 14 | $262 |
| Amarin Pharma, Inc. | 14 | $230 |
| Nestle Healthcare Nutrition Inc. | 5 | $182 |
| AstraZeneca(2 entities) | 10 | $163 |
| Recordati_rare_diseases_inc. | 8 | $126 |
| Corcept Therapeutics | 5 | $111 |
| Novartis | 4 | $92 |
| Medtronic | 4 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| IBSA Pharma Inc. | 4 | $63 |
| EUSA Pharma (US) LLC | 3 | $52 |
| Embecta Corp. | 2 | $52 |
| Exact Sciences | 2 | $46 |
| Bayer | 2 | $36 |
| BD | 1 | $33 |
| Recor Medical Inc | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| GSK | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre 2$261
- FREESTYLE LIBRE 3$179
- DEXCOM G6 TRANSMITTER$116
- ZENPEP$103
How this compares
$6,833 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $19,044 |
| TrulicityDulaglutide | 14 | $15,655 |
| Gabapentin | 33 | $674 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $401 |
| Amlodipine Besylate | 48 | $263 |
| Levothyroxine Sodium | 27 | $223 |
| Doxycycline Hyclate | 18 | $202 |
| Lisinopril | 26 | $201 |
| Simvastatin | 11 | $196 |
| Sertraline Hcl | 21 | $194 |
| Atorvastatin Calcium | 32 | $184 |
| Fluticasone Propionate | 12 | $144 |
| Losartan Potassium | 29 | $143 |
| Escitalopram Oxalate | 24 | $140 |
| Clindamycin Hcl | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,113 | $19,04419 claims |
| Lilly USA, LLCTrulicity | $262 | $15,65514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Missouri.
Other primary care in Saint Louis
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Heather BealSaint Louis$4K
- Ashley TitchenalSaint Louis$3K
- Brittany ShoultsSaint Louis$3K
- Stella HeineSaint Louis$2K
- Johnathan WieseSaint Louis$2K
- Taylor RouserSaint Louis$2K
- Faye MonahanSaint Louis$1K
- Alita BillopsSaint Louis$840
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.